Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett’s Esophagus test. TissueCypher is the first AI-driven precision medicine test designed to predict a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer.

On December 24, Shanghai Government unveiled the "Work Plan for Developing Medical Artificial Intelligence (2025–2027)" to advance the deep integration of artificial intelligence (AI) with clinical medicine and promote the application of vertical large models in diagnostic support for testing and inspection.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare & Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the ‘gapfill’ pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing for PrecisionCHD and Epi+Gen CHD based on actual cost data from Cardio Diagnostics. The Medicare contractors will report to CMS preliminary gapfill pricing for calendar year 2025 by April 1, 2025.

QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.

Canon Medical Systems USA is proud to announce the launch of its AI-powered Automation Platform, an advanced, zero-click solution that leverages deep learning technology to streamline clinical workflows. Designed to deliver fast, actionable results, this innovative platform integrates seamlessly from scanner to clinical decision-making, empowering healthcare providers with precise tools to help with patient triage and confident treatment planning.

Artificial intelligence continues to reshape healthcare, but a new study highlights the challenges of integrating AI tools into medical practice. ChatGPT-4, an AI chatbot developed by OpenAI, outperformed doctors in a diagnostic accuracy study, raising questions about how effectively physicians can use such technology.

Sheba Medical Center’s innovation arm, Accelerate, Redesign, and Collaborate (ARC), has partnered with Roche to advance the diagnosis and treatment of non-small cell lung cancer (NSCLC) by leveraging AI.

SCIEX, a global leader in life science analytical technologies, and Bioinformatics Solutions Inc. (BSI), provider of next-generation, deep learning proteomics and AI-driven biotechnology solutions, advance their collaboration with the co-development of PEAKS 12.5. This new software launch is fully compatible with the ZenoTOF 7600+ system, offering exclusive commercial support of ZT Scan DIA for proteomics applications.

Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced that Tencent has made a strategic US$30 million investment in Insighta, a Hong Kong-based early cancer detection company. This investment values Insighta at US$200 million and underscores Tencent’s endeavor to advancing AI-powered innovations in healthcare.